Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 908

1.

New drugs for non-alcoholic steatohepatitis.

Cardoso AC, de Figueiredo-Mendes C, A Villela-Nogueira C, Sanyal AJ.

Liver Int. 2020 Feb;40 Suppl 1:96-101. doi: 10.1111/liv.14354. Review.

PMID:
32077615
2.

Current management of non-alcoholic steatohepatitis.

Muthiah MD, Sanyal AJ.

Liver Int. 2020 Feb;40 Suppl 1:89-95. doi: 10.1111/liv.14355. Review.

PMID:
32077609
3.

Fecal microbiome distinguishes alcohol consumption from alcoholic hepatitis but does not discriminate disease severity.

Smirnova E, Puri P, Muthiah MD, Daitya K, Brown R, Chalasani N, Liangpunsakul S, Shah VH, Gelow K, Siddiqui MS, Boyett S, Mirshahi F, Sikaroodi M, Gillevet P, Sanyal AJ.

Hepatology. 2020 Feb 14. doi: 10.1002/hep.31178. [Epub ahead of print]

PMID:
32056227
4.

Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease.

Musolino V, Gliozzi M, Scarano F, Bosco F, Scicchitano M, Nucera S, Carresi C, Ruga S, Zito MC, Maiuolo J, Macrì R, Amodio N, Juli G, Tassone P, Mollace R, Caffrey R, Marioneaux J, Walker R, Ehrlich J, Palma E, Muscoli C, Bedossa P, Salvemini D, Mollace V, Sanyal AJ.

Sci Rep. 2020 Feb 13;10(1):2565. doi: 10.1038/s41598-020-59485-3.

5.

MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease.

Eslam M, Sanyal AJ, George J; an international consensus panel.

Gastroenterology. 2020 Feb 7. pii: S0016-5085(20)30171-2. doi: 10.1053/j.gastro.2019.11.312. [Epub ahead of print]

PMID:
32044314
6.

Successful treatment of cardiac dysrhythmia associated with foot and mouth disease in a calf.

Priyanka M, Mahendran K, Umapathi V, Dechamma HJ, Patel BHM, Reddy GR, Sanyal A.

Iran J Vet Res. 2019 Fall;20(4):304-307.

7.

Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results.

van Baar ACG, Beuers U, Wong K, Haidry R, Costamagna G, Hafedi A, Deviere J, Ghosh SS, Lopez-Talavera JC, Rodriguez L, Galvao Neto MP, Sanyal A, Bergman JJGHM.

JHEP Rep. 2019 Nov 5;1(6):429-437. doi: 10.1016/j.jhepr.2019.10.006. eCollection 2019 Dec.

8.

Non-alcoholic fatty liver disease in lean individuals.

Albhaisi S, Chowdhury A, Sanyal AJ.

JHEP Rep. 2019 Aug 30;1(4):329-341. doi: 10.1016/j.jhepr.2019.08.002. eCollection 2019 Oct. Review.

9.

Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition.

Sanyal A, DeAndrade MP, Novis HS, Lin S, Chang J, Lengacher N, Tomlinson JJ, Tansey MG, LaVoie MJ.

Mov Disord. 2020 Feb 8. doi: 10.1002/mds.27994. [Epub ahead of print]

PMID:
32034799
10.

Nonalcoholic Fatty Liver Disease.

Sanyal AJ, Siddiqui MS.

Gastroenterol Clin North Am. 2020 Mar;49(1):xiii-xiv. doi: 10.1016/j.gtc.2019.12.001. No abstract available.

PMID:
32033769
11.

Burden of Disease due to Nonalcoholic Fatty Liver Disease.

Muthiah MD, Sanyal AJ.

Gastroenterol Clin North Am. 2020 Mar;49(1):1-23. doi: 10.1016/j.gtc.2019.09.007. Review.

PMID:
32033757
12.

Erratum: FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice.

Rohrbach TD, Asgharpour A, Maczis MA, Montefusco D, Cowart LA, Bedossa P, Sanyal AJ, Spiegel S.

J Lipid Res. 2020 Feb;61(2):267. doi: 10.1194/jlr.ERR119000580. No abstract available.

13.

Immunogenicity and protective efficacy of 3A truncated negative marker foot-and-mouth disease virus serotype A vaccine.

Dhanesh VV, Hosamani M, Basagoudanavar SH, Saravanan P, Biswal JK, Tamil Selvan RP, Madhavan A, Sehrish K, Sanyal A, Sreenivasa BP.

Appl Microbiol Biotechnol. 2020 Jan 30. doi: 10.1007/s00253-020-10370-z. [Epub ahead of print]

PMID:
32002597
14.

Improvement in Quality of Life and Decrease in Large Volume Paracentesis Requirements With the Automated Low Flow Ascites Pump.

Wong F, Bendel E, Sniderman K, Frederick T, Haskal ZJ, Sanyal A, Asrani SK, Capel J, Kamath PS.

Liver Transpl. 2020 Jan 30. doi: 10.1002/lt.25724. [Epub ahead of print]

PMID:
31999044
15.

Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis.

Loomba R, Neuschwander-Tetri BA, Sanyal A, Chalasani N, Diehl AM, Terrault N, Kowdley K, Dasarathy S, Kleiner D, Behling C, Lavine J, Van Natta M, Middleton M, Tonascia J, Sirlin C; NASH Clinical Research Network.

Hepatology. 2020 Jan 21. doi: 10.1002/hep.31121. [Epub ahead of print]

PMID:
31965579
16.

Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.

Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, Goodman Z, Aithal GP, Kowdley KV, Seyedkazemi S, Fischer L, Loomba R, Abdelmalek MF, Tacke F.

Hepatology. 2020 Jan 13. doi: 10.1002/hep.31108. [Epub ahead of print]

PMID:
31943293
17.

Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.

Albhaisi S, Sanyal AJ.

Pharmaceut Med. 2019 Dec;33(6):451-463. doi: 10.1007/s40290-019-00305-z.

PMID:
31933238
18.

Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease.

Romeo S, Sanyal A, Valenti L.

Cell Metab. 2020 Jan 7;31(1):35-45. doi: 10.1016/j.cmet.2019.12.002. Review.

PMID:
31914377
19.

Farnesoid X Receptor Agonism, Acetyl-Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model.

Gapp B, Jourdain M, Bringer P, Kueng B, Weber D, Osmont A, Zurbruegg S, Knehr J, Falchetto R, Roma G, Dietrich W, Valdez R, Beckmann N, Nigsch F, Sanyal AJ, Ksiazek I.

Hepatol Commun. 2019 Nov 8;4(1):109-125. doi: 10.1002/hep4.1443. eCollection 2020 Jan.

20.

Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study.

Baratta F, Pastori D, Angelico F, Balla A, Paganini AM, Cocomello N, Ferro D, Violi F, Sanyal AJ, Del Ben M.

Clin Gastroenterol Hepatol. 2019 Dec 27. pii: S1542-3565(19)31506-X. doi: 10.1016/j.cgh.2019.12.026. [Epub ahead of print]

PMID:
31887443
21.

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.

Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, Sheikh MY, Schattenberg JM, Kayali Z, Zivony A, Sheikh A, Garcia-Samaniego J, Satapathy SK, Therapondos G, Mena E, Schuppan D, Robinson J, Chan JL, Hagerty DT, Sanyal AJ.

J Hepatol. 2019 Dec 27. pii: S0168-8278(19)30758-5. doi: 10.1016/j.jhep.2019.11.024. [Epub ahead of print]

PMID:
31887369
22.

Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.

Anstee QM, Neuschwander-Tetri BA, Wong VW, Abdelmalek MF, Younossi ZM, Yuan J, Pecoraro ML, Seyedkazemi S, Fischer L, Bedossa P, Goodman Z, Alkhouri N, Tacke F, Sanyal A.

Contemp Clin Trials. 2019 Dec 24;89:105922. doi: 10.1016/j.cct.2019.105922. [Epub ahead of print]

23.

Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension.

Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, Lawitz E, Satapathy SK, Ghabril M, Shiffman ML, Younes ZH, Thuluvath PJ, Berzigotti A, Albillos A, Robinson JM, Hagerty DT, Chan JL, Sanyal AJ; IDN-6556-14 Investigators.

J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724-X. doi: 10.1016/j.jhep.2019.12.010. [Epub ahead of print]

PMID:
31870950
24.

Longitudinal studies can identify distinct inflammatory cytokines associated with the inhibition or progression of liver cancer.

Mirshahi F, Aqbi HF, Cresswell K, Saneshaw M, Coleman C, Jacobs T, Idowu MO, Dozmorov M, Sanyal AJ, Manjili MH.

Liver Int. 2020 Feb;40(2):468-472. doi: 10.1111/liv.14323. Epub 2019 Dec 26.

PMID:
31821689
25.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators.

Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5.

PMID:
31813633
26.

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension.

Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, Noureddin M, Pyko M, Shiffman M, Sanyal A, Allgood A, Shlevin H, Horton R, Zomer E, Irish W, Goodman Z, Harrison SA, Traber PG.

Gastroenterology. 2019 Dec 5. pii: S0016-5085(19)41895-7. doi: 10.1053/j.gastro.2019.11.296. [Epub ahead of print]

27.

Efficient inhibition of foot-and-mouth disease virus replication in vitro by artificial microRNA targeting 3D polymerase.

Basagoudanavar SH, Ranjitha HB, Hosamani M, Kolangath SM, Selvan RPT, Sreenivasa BP, Saravanan P, Sanyal A, Venkataramanan R.

Acta Virol. 2019;63(4):475-479. doi: 10.4149/av_2019_407.

PMID:
31802691
28.

An Open Label, Dose Escalation Study To Assess The Safety And Efficacy Of IL-22 Agonist F-652 In Patients With Alcoholic Hepatitis.

Arab JP, Sehrawat TS, Simonetto DA, Verma VK, Feng D, Tang T, Dreyer K, Yan X, Daley WL, Sanyal A, Chalasani N, Radaeva S, Yang L, Vargas H, Ibacache M, Gao B, Gores GJ, Malhi H, Kamath PS, Shah VH.

Hepatology. 2019 Nov 27. doi: 10.1002/hep.31046. [Epub ahead of print]

PMID:
31774566
29.

Corrigendum to "Generation of acid resistant virus like particles of vaccine strains of foot-and-mouth disease virus (FMDV)" [Biologicals 60 (2019) 28-35].

Selvaraj DPR, Saravanan P, Biswal JK, Basagoudanavar SH, Dechamma HJ, Umapathi V, Sreenivasa BP, Tamilselvan RP, Krishnaswamy N, Zaffer I, Sanyal A.

Biologicals. 2020 Jan;63:106. doi: 10.1016/j.biologicals.2019.11.003. Epub 2019 Nov 22. No abstract available.

PMID:
31767491
30.

Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis.

Bajaj JS, Salzman N, Acharya C, Takei H, Kakiyama G, Fagan A, White MB, Gavis EA, Holtz ML, Hayward M, Nittono H, Hylemon PB, Cox IJ, Williams R, Taylor-Robinson SD, Sterling RK, Matherly SC, Fuchs M, Lee H, Puri P, Stravitz RT, Sanyal AJ, Ajayi L, Le Guennec A, Atkinson RA, Siddiqui MS, Luketic V, Pandak WM, Sikaroodi M, Gillevet PM.

JCI Insight. 2019 Dec 19;4(24). pii: 133410. doi: 10.1172/jci.insight.133410.

31.

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.

Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Ratziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM.

Contemp Clin Trials. 2020 Jan;88:105889. doi: 10.1016/j.cct.2019.105889. Epub 2019 Nov 13.

PMID:
31731005
32.

Differential antibody responses to the major antigenic sites of FMD virus serotype O after primo-vaccination, multiply-vaccination and after natural exposure.

Biswal JK, Subramaniam S, Ranjan R, VanderWaal K, Sanyal A, Pattnaik B, Singh RK.

Infect Genet Evol. 2020 Mar;78:104105. doi: 10.1016/j.meegid.2019.104105. Epub 2019 Nov 6.

PMID:
31706082
33.

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.

Harrison SA, Alkhouri N, Davison BA, Sanyal A, Edwards C, Colca JR, Lee BH, Loomba R, Cusi K, Kolterman O, Cotter G, Dittrich HC.

J Hepatol. 2019 Nov 4. pii: S0168-8278(19)30650-6. doi: 10.1016/j.jhep.2019.10.023. [Epub ahead of print]

PMID:
31697972
34.

The use of cell free DNA in the diagnosis of HCC.

Banini BA, Sanyal AJ.

Hepatoma Res. 2019;5. pii: 34. doi: 10.20517/2394-5079.2019.30. Epub 2019 Sep 23.

35.

Role of gut microbiota in liver disease.

Albhaisi SAM, Bajaj JS, Sanyal AJ.

Am J Physiol Gastrointest Liver Physiol. 2020 Jan 1;318(1):G84-G98. doi: 10.1152/ajpgi.00118.2019. Epub 2019 Oct 28.

PMID:
31657225
36.

Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.

Siddiqui MS, Van Natta ML, Connelly MA, Vuppalanchi R, Neuschwander-Tetri BA, Tonascia J, Guy C, Loomba R, Dasarathy S, Wattacheril J, Chalasani N, Sanyal AJ; NASH CRN.

J Hepatol. 2020 Jan;72(1):25-33. doi: 10.1016/j.jhep.2019.10.006. Epub 2019 Oct 18.

37.

Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.

Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, Cummings O, Yeh M, Gill R, Chalasani N, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Terrault N, Kowdley K, Loomba R, Belt P, Tonascia J, Lavine JE, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network.

JAMA Netw Open. 2019 Oct 2;2(10):e1912565. doi: 10.1001/jamanetworkopen.2019.12565.

38.

Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels.

Gawrieh S, Wilson LA, Cummings OW, Clark JM, Loomba R, Hameed B, Abdelmalek MF, Dasarathy S, Neuschwander-Tetri BA, Kowdley K, Kleiner D, Doo E, Tonascia J, Sanyal A, Chalasani N; and the NASH Clinical Research Network.

Am J Gastroenterol. 2019 Oct;114(10):1626-1635. doi: 10.14309/ajg.0000000000000388.

PMID:
31517638
39.

Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease.

Hoang SA, Oseini A, Feaver RE, Cole BK, Asgharpour A, Vincent R, Siddiqui M, Lawson MJ, Day NC, Taylor JM, Wamhoff BR, Mirshahi F, Contos MJ, Idowu M, Sanyal AJ.

Sci Rep. 2019 Aug 29;9(1):12541. doi: 10.1038/s41598-019-48746-5.

40.

Orthogonally "Clickable" Biodegradable Nanofibers: Tailoring Biomaterials for Specific Protein Immobilization.

Kalaoglu-Altan OI, Sanyal R, Sanyal A.

ACS Omega. 2019 Jan 3;4(1):121-129. doi: 10.1021/acsomega.8b03041. eCollection 2019 Jan 31.

41.

Intraoperative right coronary artery obstruction due to aortic root prosthesis mismatch after aortic valve replacement-A case report.

Agrawal AM, Arora D, Sanyal A, Lohchab SS.

J Card Surg. 2019 Nov;34(11):1396-1398. doi: 10.1111/jocs.14227. Epub 2019 Aug 23.

PMID:
31441546
42.
43.

Foot-and-Mouth Disease Virus: Immunobiology, Advances in Vaccines and Vaccination Strategies Addressing Vaccine Failures-An Indian Perspective.

Singh RK, Sharma GK, Mahajan S, Dhama K, Basagoudanavar SH, Hosamani M, Sreenivasa BP, Chaicumpa W, Gupta VK, Sanyal A.

Vaccines (Basel). 2019 Aug 16;7(3). pii: E90. doi: 10.3390/vaccines7030090. Review.

44.

Pathogenesis of NASH: The Impact of Multiple Pathways.

Noureddin M, Sanyal AJ.

Curr Hepatol Rep. 2018 Dec;17(4):350-360. doi: 10.1007/s11901-018-0425-7. Epub 2018 Oct 31.

45.

Misdiagnosis of Lyme Disease With Unnecessary Antimicrobial Treatment Characterizes Patients Referred to an Academic Infectious Diseases Clinic.

Kobayashi T, Higgins Y, Samuels R, Moaven A, Sanyal A, Yenokyan G, Lantos PM, Melia MT, Auwaerter PG.

Open Forum Infect Dis. 2019 Jul 1;6(7). pii: ofz299. doi: 10.1093/ofid/ofz299.

46.

Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD.

Rinella ME, Tacke F, Sanyal AJ, Anstee QM; participants of the AASLD/EASL Workshop.

J Hepatol. 2019 Oct;71(4):823-833. doi: 10.1016/j.jhep.2019.04.019. Epub 2019 Jul 9. Review.

PMID:
31300231
47.

Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD.

Rinella ME, Tacke F, Sanyal AJ, Anstee QM; participants of the AASLD/EASL Workshop.

Hepatology. 2019 Oct;70(4):1424-1436. doi: 10.1002/hep.30782. Epub 2019 Jul 9.

PMID:
31287572
48.

REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.

Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z.

Contemp Clin Trials. 2019 Sep;84:105803. doi: 10.1016/j.cct.2019.06.017. Epub 2019 Jun 29.

49.

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.

Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A.

Aliment Pharmacol Ther. 2019 Jul;50(2):193-203. doi: 10.1111/apt.15316. Epub 2019 Jun 10.

50.

Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.

Huapaya JA, Silhan L, Pinal-Fernandez I, Casal-Dominguez M, Johnson C, Albayda J, Paik JJ, Sanyal A, Mammen AL, Christopher-Stine L, Danoff SK.

Chest. 2019 Nov;156(5):896-906. doi: 10.1016/j.chest.2019.05.023. Epub 2019 Jun 22.

PMID:
31238042

Supplemental Content

Loading ...
Support Center